Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, Müller S, Popp O, Kull M, Haji M, Gütschow M, Döhner H, Walther W, Keller U, Bullinger L, Mertins P, Krönke J.
Ng YLD, et al. Among authors: conrad t.
Nat Commun. 2022 Feb 23;13(1):1009. doi: 10.1038/s41467-022-28515-1.
Nat Commun. 2022.
PMID: 35197447
Free PMC article.